César Filho

Oncology is currently one of the biggest health challenges in Brazil. Since 2003, cancer has become the second leading cause of death after cardiovascular disease. The cancer journey is complex, fragmented and with little guidance. Highly intensive treatment causes side effects that affect both patients' quality of life and their ability to adhere to treatment, directly impacting the chances of a cure.

César Natalio de Freitas Filho felt the urgency to improve the journey of cancer patients after his mother developed the disease and had to deal with the challenges of treatment in the public health system. So in 2016, he founded WeCancer, a pioneer in Brazil that provides a remote monitoring system for cancer patients. The company has positively impacted more than 60,000 patients and has received investments from Hospital Israelita Albert Einstein and VOX Capital, a fund dedicated to social impact. In addition, WeCancer has established strategic partnerships with major global pharmaceutical companies, including Pfizer, Roche, Daiichi Sankyo and AstraZeneca. It has also established collaborations with leading hospitals, such as Beneficência Portuguesa in São Paulo. Since 2018, WeCancer has had a partnership with the Harvard Global Health Institute, which allows Harvard students to participate in internships during academic breaks in the United States each year.

With a degree in Biological Sciences from the Federal University of Espírito Santo, César has already received several recognitions for his creation. He was also selected by McKinsey as one of the highlights in Brazil in 2020, and the following year was included in the Lemann Foundation's list of leaders, which brings together other outstanding young Brazilians.